<?xml version="1.0" encoding="UTF-8"?>
<p>Patients were stratified by gender and randomly assigned (1 : 1) to receive either NEPA or APR/GRAN treatment (
 <xref ref-type="supplementary-material" rid="sup2">supplementary Table S1</xref>, available at 
 <italic>Annals of Oncology</italic> online). Granisetron 3 mg is the registered dose in China.
</p>
